PT3894549T - Transposase piggybac mutada - Google Patents
Transposase piggybac mutadaInfo
- Publication number
- PT3894549T PT3894549T PT198327777T PT19832777T PT3894549T PT 3894549 T PT3894549 T PT 3894549T PT 198327777 T PT198327777 T PT 198327777T PT 19832777 T PT19832777 T PT 19832777T PT 3894549 T PT3894549 T PT 3894549T
- Authority
- PT
- Portugal
- Prior art keywords
- mutational
- piggybac transposase
- piggybac
- transposase
- mutational piggybac
- Prior art date
Links
- 102000008579 Transposases Human genes 0.000 title 1
- 108010020764 Transposases Proteins 0.000 title 1
- 230000000869 mutational effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777325P | 2018-12-10 | 2018-12-10 | |
| US201962925516P | 2019-10-24 | 2019-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3894549T true PT3894549T (pt) | 2024-10-16 |
Family
ID=69143664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT198327777T PT3894549T (pt) | 2018-12-10 | 2019-12-09 | Transposase piggybac mutada |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12570966B2 (enExample) |
| EP (1) | EP3894549B1 (enExample) |
| JP (1) | JP7441840B2 (enExample) |
| KR (1) | KR102999228B1 (enExample) |
| CN (2) | CN113195712B (enExample) |
| AU (2) | AU2019398101B2 (enExample) |
| BR (1) | BR112021011063A2 (enExample) |
| CA (1) | CA3121268A1 (enExample) |
| CL (3) | CL2021001488A1 (enExample) |
| DK (1) | DK3894549T3 (enExample) |
| ES (1) | ES2991895T3 (enExample) |
| FI (1) | FI3894549T3 (enExample) |
| HU (1) | HUE068630T2 (enExample) |
| IL (1) | IL283314A (enExample) |
| LT (1) | LT3894549T (enExample) |
| MX (1) | MX2021006783A (enExample) |
| PL (1) | PL3894549T3 (enExample) |
| PT (1) | PT3894549T (enExample) |
| SG (1) | SG11202106049RA (enExample) |
| SI (1) | SI3894549T1 (enExample) |
| TW (1) | TWI862531B (enExample) |
| WO (1) | WO2020123327A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3124522B1 (fr) * | 2021-06-25 | 2025-02-28 | Cherbonneau Francois | Composition et méthode permettant l’édition génomique |
| WO2023122716A1 (en) * | 2021-12-22 | 2023-06-29 | Vanderbilt University | Next generation transpososomes |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| CN121127601A (zh) * | 2023-05-12 | 2025-12-12 | 隆萨生物制剂股份有限公司 | 使用转座酶进行混合瞬时转染以用于高产率产物生产 |
| AU2024300966A1 (en) | 2023-07-21 | 2026-01-08 | Amgen Inc. | Vectors incorporating a combination of promoters driving selectable marker expression |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN120737218B (zh) * | 2025-08-15 | 2026-01-06 | 云南彤宁生物制药技术有限公司 | 融合蛋白、调控系统及利用该系统构建转基因细胞的方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| NZ330926A (en) | 1996-01-11 | 1999-11-29 | Immunex Corp | Expression augmenting sequence elements (ease) for eukaryotic expression systems |
| US6218185B1 (en) | 1996-04-19 | 2001-04-17 | The United States Of America As Represented By The Secretary Of Agriculture | Piggybac transposon-based genetic transformation system for insects |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7105343B1 (en) | 2000-10-31 | 2006-09-12 | University Of Notre Dame Du Lac | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac |
| AU2003268022B2 (en) | 2002-07-24 | 2009-02-05 | Manoa Biosciences Inc. | Transposon-based vectors and methods of nucleic acid integration |
| US7932088B1 (en) | 2005-04-25 | 2011-04-26 | University Of Notre Dame Du Lac | High efficiency transformation of Plasmodium falciparum by the lepidopteran transposon, piggyBac |
| WO2007100821A2 (en) | 2006-02-28 | 2007-09-07 | University Of Notre Dame | Piggybac constructs in vertebrates |
| US20090042297A1 (en) | 2007-06-01 | 2009-02-12 | George Jr Alfred L | Piggybac transposon-based vectors and methods of nucleic acid integration |
| WO2010085699A2 (en) | 2009-01-23 | 2010-07-29 | The Johns Hopkins University | Mammalian piggybac transposon and methods of use |
| CA2750027C (en) | 2009-01-23 | 2020-11-10 | Nsgene A/S | Improved cell lines and their use in encapsulated cell biodelivery |
| US20110311506A1 (en) | 2009-02-25 | 2011-12-22 | The Johns Hopkins University | Piggybac transposon variants and methods of use |
| EP4733396A2 (en) | 2009-02-26 | 2026-04-29 | Poseida Therapeutics, Inc. | Hyperactive piggybac transposases |
| US20100311116A1 (en) | 2009-06-04 | 2010-12-09 | Excellgene Sa | Fast generation of high expression stable cell lines expressing recombinant proteins under minimal and short-term selective pressure |
| CN102803484A (zh) | 2009-06-11 | 2012-11-28 | 大学共同利用机关法人情报·系统研究机构 | 生产蛋白质的方法 |
| JP2013519652A (ja) * | 2010-02-12 | 2013-05-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | 単一ユニット抗体精製 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| GB201014169D0 (en) | 2010-08-25 | 2010-10-06 | Cambridge Entpr Ltd | In vitro hepatic differentiation |
| WO2012074758A1 (en) | 2010-11-16 | 2012-06-07 | Transposagen Bioharmaceuticals, Inc. | Hyperactive piggybac transposases |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US9783790B2 (en) * | 2011-07-15 | 2017-10-10 | The Johns Hopkins University | Trichoplusia ni piggybac transposases with reduced integration activity |
| WO2013019625A2 (en) | 2011-07-29 | 2013-02-07 | The University Of Wyoming | Methods of using a bacterial glcnac-6-p 2'-epimerase to promote sialylation of glycoconjugates |
| US9796974B2 (en) | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| DK2951309T3 (en) | 2013-02-01 | 2019-04-23 | Selexis Sa | INCREASED TRANSGEN EXPRESSION AND PROCESSING |
| US20160015749A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
| CN103360464A (zh) | 2013-07-17 | 2013-10-23 | 武汉摩尔生物科技有限公司 | 多肽、编码该多肽的dna分子、载体、制备方法及应用 |
| US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| HUE052552T2 (hu) * | 2014-04-09 | 2021-05-28 | Dna Twopointo Inc | Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| CN105154473B (zh) | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合系统及其用途 |
| LT3359671T (lt) | 2015-10-08 | 2021-12-10 | Dna Twopointo Inc. | Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai |
| CA3004665C (en) | 2015-12-14 | 2021-08-24 | GenomeFrontier Therapeutics, Inc. | Transposon system, kit comprising the same, and uses thereof |
| JP2019506177A (ja) | 2016-02-26 | 2019-03-07 | ポセイダ セラピューティクス， インコーポレイテッド | トランスポゾン系および使用方法 |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| CN110402305B (zh) | 2016-11-30 | 2023-07-21 | 北京复昇生物科技有限公司 | 一种crispr文库筛选的方法 |
| US20210115453A1 (en) | 2017-08-31 | 2021-04-22 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| SG11202105900UA (en) | 2018-12-10 | 2021-07-29 | Amgen Inc | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
-
2019
- 2019-12-09 HU HUE19832777A patent/HUE068630T2/hu unknown
- 2019-12-09 US US17/299,000 patent/US12570966B2/en active Active
- 2019-12-09 CA CA3121268A patent/CA3121268A1/en active Pending
- 2019-12-09 CN CN201980081292.7A patent/CN113195712B/zh active Active
- 2019-12-09 DK DK19832777.7T patent/DK3894549T3/da active
- 2019-12-09 EP EP19832777.7A patent/EP3894549B1/en active Active
- 2019-12-09 CN CN202411173681.1A patent/CN118995660A/zh active Pending
- 2019-12-09 PT PT198327777T patent/PT3894549T/pt unknown
- 2019-12-09 KR KR1020217021154A patent/KR102999228B1/ko active Active
- 2019-12-09 JP JP2021532224A patent/JP7441840B2/ja active Active
- 2019-12-09 SI SI201930822T patent/SI3894549T1/sl unknown
- 2019-12-09 FI FIEP19832777.7T patent/FI3894549T3/fi active
- 2019-12-09 BR BR112021011063-1A patent/BR112021011063A2/pt unknown
- 2019-12-09 WO PCT/US2019/065129 patent/WO2020123327A1/en not_active Ceased
- 2019-12-09 MX MX2021006783A patent/MX2021006783A/es unknown
- 2019-12-09 LT LTEPPCT/US2019/065129T patent/LT3894549T/lt unknown
- 2019-12-09 ES ES19832777T patent/ES2991895T3/es active Active
- 2019-12-09 AU AU2019398101A patent/AU2019398101B2/en active Active
- 2019-12-09 PL PL19832777.7T patent/PL3894549T3/pl unknown
- 2019-12-09 SG SG11202106049RA patent/SG11202106049RA/en unknown
- 2019-12-10 TW TW108145098A patent/TWI862531B/zh active
-
2021
- 2021-05-20 IL IL283314A patent/IL283314A/en unknown
- 2021-06-08 CL CL2021001488A patent/CL2021001488A1/es unknown
-
2023
- 2023-11-09 CL CL2023003339A patent/CL2023003339A1/es unknown
-
2025
- 2025-12-19 CL CL2025004022A patent/CL2025004022A1/es unknown
-
2026
- 2026-03-12 AU AU2026201887A patent/AU2026201887A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202106049RA (en) | 2021-07-29 |
| AU2026201887A1 (en) | 2026-04-02 |
| CL2025004022A1 (es) | 2026-04-10 |
| CA3121268A1 (en) | 2020-06-18 |
| CL2023003339A1 (es) | 2024-06-07 |
| CL2021001488A1 (es) | 2021-11-26 |
| DK3894549T3 (da) | 2024-10-14 |
| SI3894549T1 (sl) | 2024-10-30 |
| BR112021011063A2 (pt) | 2021-08-31 |
| JP2022512332A (ja) | 2022-02-03 |
| MX2021006783A (es) | 2021-07-15 |
| ES2991895T3 (es) | 2024-12-05 |
| EP3894549A1 (en) | 2021-10-20 |
| KR20210101270A (ko) | 2021-08-18 |
| US20220064610A1 (en) | 2022-03-03 |
| CN113195712B (zh) | 2024-09-13 |
| IL283314A (en) | 2021-07-29 |
| FI3894549T3 (fi) | 2024-10-23 |
| JP7441840B2 (ja) | 2024-03-01 |
| LT3894549T (lt) | 2024-09-25 |
| KR102999228B1 (ko) | 2026-07-31 |
| AU2019398101A1 (en) | 2021-06-10 |
| HUE068630T2 (hu) | 2025-01-28 |
| AU2019398101B2 (en) | 2025-12-18 |
| EP3894549B1 (en) | 2024-07-31 |
| PL3894549T3 (pl) | 2024-11-25 |
| TWI862531B (zh) | 2024-11-21 |
| TW202035687A (zh) | 2020-10-01 |
| WO2020123327A1 (en) | 2020-06-18 |
| CN113195712A (zh) | 2021-07-30 |
| CN118995660A (zh) | 2024-11-22 |
| US12570966B2 (en) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3801265B1 (en) | URINARY FLOWMETER | |
| IL280913A (en) | Novel methods | |
| EP3890716A4 (en) | COMBINATION THERAPIES | |
| IL280912A (en) | Novel methods | |
| EP3849534A4 (en) | COMBINATION THERAPIES | |
| EP3846674C0 (en) | VAGINAL SPECULUM | |
| EP3555124C0 (en) | TCR NYESO | |
| IL257294A (en) | Coupleable crate | |
| DK3894549T3 (da) | Muteret piggybac-transposase | |
| EP3781060A4 (en) | CRYOPROBE | |
| UA40089S (uk) | Кальян | |
| EP3872558A4 (en) | OPTICAL ISOLATOR | |
| EP3784463A4 (en) | Fluorosulfones | |
| EP3810860C0 (en) | COUPLER | |
| EP3792200A4 (en) | TANK TANK | |
| EP3745904C0 (de) | Stockgriff | |
| EP3878374A4 (en) | OKKLUDER | |
| EP3721129A4 (en) | CRYOSPHERE | |
| EP3903200A4 (en) | DATE EXTRACTOR | |
| UA38744S (uk) | Монітор | |
| HRP20260316T1 (hr) | Postupak akvakulture | |
| EP3844177A4 (en) | COMBINATION THERAPIES | |
| DK3587968T3 (da) | Fluidsystem | |
| DK3752258T3 (da) | Trampolin | |
| EP3773733C0 (en) | METALLO-LIOTHYRONINE |